{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:12:34Z","timestamp":1792131154540,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005942","name":"Funda\u00e7\u00e3o Butantan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005942","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Butantan-DV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dengue is caused by infection with 1 of 4 dengue virus (DENV) serotypes (DENV-1 to DENV-4). V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, double-blind, active comparator\u2013controlled, multisite, phase 2 trial, we compared the safety and immunogenicity of V181 and Butantan-DV in healthy adults in Brazil. The primary immunogenicity objectives were to compare vaccine-induced neutralizing antibody geometric mean titers (GMTs) and seroconversion rates for DENV-1 to DENV-4 at day 28 postvaccination. The primary and secondary safety objectives, respectively, were to assess vaccine-related serious adverse events and the proportion of participants experiencing solicited adverse events through day 28 postvaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1364 participants were assigned (1:1) to receive V181 (n = 682) or Butantan-DV (n = 682). At day 28 postvaccination, V181 induced a noninferior immune response to Butantan-DV for DENV-1 and DENV-2 but not DENV-3 and DENV-4, as measured using GMT ratios. Noninferiority was established for all DENV serotypes based on seroconversion rates. Most participants developed a trivalent or tetravalent neutralizing antibody response. Vaccine viremia was detected for each DENV serotype. V181 and Butantan-DV were generally well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>V181 was immunogenic in adults, and while immunogenicity was noninferior to Butantan-DV for DENV-1 and DENV-2, seroconversion rates were noninferior for DENV-1 to DENV-4. The safety profile of V181 is comparable to that of Butantan-DV and supports its continued evaluation as a single-dose quadrivalent vaccine for dengue prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT05710224<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag349","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:22:34Z","timestamp":1781695354000},"page":"e629-e638","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial"],"prefix":"10.1093","volume":"83","author":[{"given":"David","family":"Alexanderian","sequence":"first","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano","family":"Ramos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital S\u00e3o Lucas da PUC do Rio Grande do Sul , Porto Alegre ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3628-3738","authenticated-orcid":false,"given":"Soumya","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-6288","authenticated-orcid":false,"given":"Alexandre Vargas","family":"Schwarzbold","sequence":"additional","affiliation":[{"name":"Universidade Federal de Santa Maria School of Medicine, Department of Health Sciences, , Santa Maria ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Loch","sequence":"additional","affiliation":[{"name":"Instituto Butantan , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane Cristina Barboza","family":"Zanetti","sequence":"additional","affiliation":[{"name":"Instituto Butantan , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxu","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Martin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8177-2456","authenticated-orcid":false,"given":"Matthew T","family":"Onorato","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-3001","authenticated-orcid":false,"given":"Germ\u00e1n","family":"\u00c1\u00f1ez","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. MRL, , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026100713442599800_ciag349-B1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Wilder-Smith","year":"2019","journal-title":"Lancet"},{"key":"2026100713442599800_ciag349-B2","doi-asserted-by":"crossref","first-page":"105710","DOI":"10.1016\/j.meegid.2024.105710","article-title":"Dengue virus: etiology, epidemiology, pathobiology, and developments in diagnosis and control\u2014a comprehensive review","volume":"127","author":"Pourzangiabadi","year":"2025","journal-title":"Infect Genet Evol"},{"key":"2026100713442599800_ciag349-B3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1751-2824.2012.01602.x","article-title":"Dengue virus and other arboviruses: a global view of risks","volume":"7","author":"Anez","year":"2012","journal-title":"ISBT Sci Series"},{"key":"2026100713442599800_ciag349-B4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2026100713442599800_ciag349-B5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4161\/hv.7.6.14985","article-title":"Vaccines for the prevention of dengue: development update","volume":"7","author":"Thomas","year":"2011","journal-title":"Hum Vaccin"},{"key":"2026100713442599800_ciag349-B6","doi-asserted-by":"crossref","first-page":"678645","DOI":"10.1155\/2013\/678645","article-title":"Dengue in the United States of America: a worsening scenario?","volume":"2013","author":"A\u00f1ez","year":"2013","journal-title":"Biomed Res Int"},{"key":"2026100713442599800_ciag349-B7","author":"European Centre for Disease Prevention and Control"},{"key":"2026100713442599800_ciag349-B8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100713442599800_ciag349-B9","volume-title":"Prescribing information","author":"Dengvaxia (dengue tetravalent vaccine, live)"},{"key":"2026100713442599800_ciag349-B10","volume-title":"Summary of product characteristics","author":"Dengvaxia (dengue tetravalent vaccine, live)","year":"2023"},{"key":"2026100713442599800_ciag349-B11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"2026100713442599800_ciag349-B12","volume-title":"Dengue tetravalent vaccine (live, attenuated). Summary of product characteristics","author":"EMA. Qdenga","year":"2022"},{"key":"2026100713442599800_ciag349-B13","author":"Butantan"},{"key":"2026100713442599800_ciag349-B14","doi-asserted-by":"crossref","first-page":"2046960","DOI":"10.1080\/21645515.2022.2046960","article-title":"A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-na\u00efve and flavivirus-experienced healthy adults","volume":"18","author":"Russell","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2026100713442599800_ciag349-B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2020.09.005","article-title":"Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003\/TV005","volume":"43","author":"Durbin","year":"2020","journal-title":"Curr Opin Virol"},{"key":"2026100713442599800_ciag349-B16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"key":"2026100713442599800_ciag349-B17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan-Dengue Vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100713442599800_ciag349-B18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"2026100713442599800_ciag349-B19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the National Institute of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"key":"2026100713442599800_ciag349-B20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"2026100713442599800_ciag349-B21","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","article-title":"Efficacy and safety of Butantan-DV in participants aged 2\u201359 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil","volume":"24","author":"Nogueira","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026100713442599800_ciag349-B22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/s41591-026-04255-3","article-title":"Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine","volume":"32","author":"Kall\u00e1s","year":"2026","journal-title":"Nat Med"},{"key":"2026100713442599800_ciag349-B23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4269\/ajtmh.17-0948","article-title":"Virus reduction neutralization test: a single-cell imaging high-throughput virus neutralization assay for dengue","volume":"99","author":"Whiteman","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2026100713442599800_ciag349-B24","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1128\/JCM.43.10.4977-4983.2005","article-title":"Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay","volume":"43","author":"Johnson","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2026100713442599800_ciag349-B25","author":"US Department of Health and Human Services; US Food and Drug Administration; Center for Biologics Evaluation and Research"},{"key":"2026100713442599800_ciag349-B26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"2026100713442599800_ciag349-B27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kall\u00e1s","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026100713442599800_ciag349-B28","doi-asserted-by":"crossref","first-page":"e0005584","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2026100713442599800_ciag349-B29","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jid.2024.11.015","article-title":"Localized inflammation in dengue vaccine\u2013induced skin rash is not associated with continuous presence of dengue virus genome","volume":"145","author":"Strother","year":"2025","journal-title":"J Investig Dermatol"},{"key":"2026100713442599800_ciag349-B30","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026100713442599800_ciag349-B31","doi-asserted-by":"crossref","first-page":"e173328","DOI":"10.1172\/JCI173328","article-title":"TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies","volume":"134","author":"Pierce","year":"2024","journal-title":"J Clin Invest"},{"key":"2026100713442599800_ciag349-B32","author":"Governo do Estado Rio Grande do Sul"},{"key":"2026100713442599800_ciag349-B33","author":"National Library of Medicine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag349\/68664971\/ciag349.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e629\/68664971\/ciag349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e629\/68664971\/ciag349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:44:39Z","timestamp":1791395079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/3\/e629\/8722907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag349","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,7,1]]}}}